Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes

Category	Detail
Condition	Atherosclerotic cardiovascular disease (ASCVD)
Key Mechanisms	Inclisiran is an siRNA targeting hepatic PCSK9 mRNA, reducing PCSK9 expression and lowering LDL-C levels
Target Population	Patients with established ASCVD and LDL-C ≥ 70 mg/dL on high-intensity statin therapy, with or without ezetimibe
Care Setting	Secondary prevention in clinical cardiovascular care settings

Inclisiran predicted to reduce LDL-C by approximately 49.7% versus placebo over 5 years in virtual ASCVD patients
SIRIUS in-silico model forecasts a 25.2% relative reduction in 3-point major adverse cardiovascular events (MACE) with inclisiran
Predicted reductions include myocardial infarction by 34.8%, ischemic stroke by 26%, and major adverse limb events by 34.1%

Identify patients with established ASCVD and LDL-C ≥ 70 mg/dL despite maximally tolerated statin and ezetimibe therapy

Consider PCSK9 inhibition with inclisiran as adjunct therapy to high-intensity statins (± ezetimibe) for LDL-C lowering
Administer inclisiran twice yearly after initial and 3-month doses to maintain LDL-C reduction

Monitor LDL-C levels to assess efficacy of inclisiran therapy
Observe for cardiovascular events including myocardial infarction, ischemic stroke, and major adverse limb events

Model did not account for non-adherence, recurrent events, or adverse effects; clinical monitoring remains essential

Virtual patients with established ASCVD and LDL-C ≥ 70 mg/dL on high-intensity statins with or without ezetimibe

Inclisiran predicted to significantly reduce LDL-C and lower risk of major cardiovascular events over 5 years; twice-yearly dosing supports adherence

Use mechanistic in-silico models to complement clinical trial data in predicting cardiovascular outcomes of lipid-lowering therapies
Combine inclisiran with maximally tolerated statin therapy and ezetimibe when LDL-C targets are not met
Apply twice-yearly inclisiran dosing regimen following initial loading doses for sustained LDL-C reduction
Continue monitoring for cardiovascular events and adjust therapy accordingly
Await results from ongoing Phase 3 cardiovascular outcomes trials (ORION-4, VICTORION-2-Prevent) for definitive clinical efficacy data

Clinical Scorecard: Forecasting the Effectiveness of Inclisiran in Individuals with Established Atherosclerotic Cardiovascular Disease: Insights from the SIRIUS In-Silico Model of Cardiovascular Outcomes